Eric Easom insider trades
Open-market stock purchases and sales by Eric Easom, Chief Executive Officer at AN2 Therapeutics, Inc, from SEC Form 4 filings since Mar 29, 2022.
Track record: 67% of 3 scored buys are up 5% or more since purchase, averaging +170%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc | Bought (not open market) | $977K |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc | Sold (not open market) | $1.6M |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc | Bought (not open market) | $880K |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc | Sold (not open market) | $3.9M |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc | Bought (not open market) | $1M |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc | Sold (not open market) | $3.2M |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc | Bought (not open market) | — |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc | Bought (not open market) | — |
Companies traded
- ANTX AN2 Therapeutics, Inc: 3 buys, 23 sales, last Mar 19, 2026